Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles

References

• Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 1991; 88: 7595–7599
   PubMed Web of Science ®Google Scholar
• Bander NH. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58: 4055–4060
   PubMed Web of Science ®Google Scholar
• Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717–1721
   PubMed Web of Science ®Google Scholar
• Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23(21)4567–4569
   PubMedGoogle Scholar
• Barren RJ, 3d, Holmes EH, Boynton AL, Misrock SL, Murphy GP. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 1997; 30(1)65–68
   PubMed Web of Science ®Google Scholar
• Carter T, Sterling-Levis K, Kim O, Doughty L, Hattarki M, Shapira D, Hewish D, Kortt AA, Russell PJ. Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody. Cancer Immunol Immunother 2004; 53: 533–542
   PubMed Web of Science ®Google Scholar
• Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999a; 59(13)3192–3198
   PubMed Web of Science ®Google Scholar
• Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999b; 5: 2674–2681
   PubMed Web of Science ®Google Scholar
• Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J, Goldenberg DM. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 2002; 1: 553–563
   PubMed Web of Science ®Google Scholar
• Crooke ST. An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 1998; 8: 115–122
   PubMedGoogle Scholar
• Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, Becker M, Marquez C, Knox S. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996; 2: 1289–12967
   PubMed Web of Science ®Google Scholar
• Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients. Prostate 1998; 37: 261–269
   PubMed Web of Science ®Google Scholar
• Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligonucleotides. Anticancer Drug Des 1997; 12: 383–393
   PubMedGoogle Scholar
• Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ. A prostate specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004; 64(21)7995–8001
   PubMed Web of Science ®Google Scholar
• Horoszewich JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927–936
   PubMed Web of Science ®Google Scholar
• Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807–1811
   PubMed Web of Science ®Google Scholar
• Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814S–819S
   PubMed Web of Science ®Google Scholar
• Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022–7032
   PubMed Web of Science ®Google Scholar
• Khan D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, Maguire RT. 111-indium capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The Prosta Scint Study Group. J Urol 1998; 159: 2041–2046
   PubMed Web of Science ®Google Scholar
• Liu H, Moy P, kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57: 3629–3634
   PubMed Web of Science ®Google Scholar
• Liu H, Rajasekeran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. Constitutive and antibody-induced internalization of prostate specific membrane antigen. Cancer Res 1998; 58: 4055–4060
   PubMed Web of Science ®Google Scholar
• Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of site specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 1990; 50: 6423–6429
   PubMed Web of Science ®Google Scholar
• McDevitte MR, Barenswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW, Jr., Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA. An alpha-particle emitting antibody ([213Bi] J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60(21)6095–6100
   PubMed Web of Science ®Google Scholar
• Mirochnik Y, Rubenstein M, Guinan P. Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen. Drug Deliv 2004; 11(3)161–165
   PubMed Web of Science ®Google Scholar
• Moffatt S, Papasakelariou C, Wiehle S, Cristiano R. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate. Gene Ther 2006; 13: 761–772
   PubMed Web of Science ®Google Scholar
• Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, O'donoghue JA, Livingston P, Larson S, Scher HI. Pilot trial of unlabeled and indium-111-labeled anti-prostate specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005; 11(20)7454–7461
   PubMed Web of Science ®Google Scholar
• Murphy GP, Greene TG, Tino WT, Boyton AL, Holmes EH. Isolation and characterization of monoclonal antibodies specific for extracellular domain of prostate specific membrane antigen. J Urol 1998; 160: 2396–2401
   PubMed Web of Science ®Google Scholar
• Nargund V, Al Hashmi D, Kumar P, Gordon S, Otitie U, Ellison D, Carrol M, Baithun S, Britton KE. Imaging with radiolabeled monoclonal antibody (MUJ591) to prostate specific membrane antigen in staging of clinically localized prostatic carcinoma: Comparison with clinical, surgical and hisological staging. BJU Int 2005; 95(9)1232–1236
   PubMed Web of Science ®Google Scholar
• Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 1998; 23: 672–677
   PubMed Web of Science ®Google Scholar
• Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003; 14: 4835–4845
   PubMed Web of Science ®Google Scholar
• Reilly RM, Sandhu J, Alvares-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Clin Pharmacokinet 1995; 28(2)126–142
   PubMed Web of Science ®Google Scholar
• Rubenstein M, Mirochnik Y, Guinan P. Delivery of biotinylated agents to prostate cancer cells utilizing hybrid monoclonal antibodies. Oligonucleotide and gene therapy-based antisense therapeutics with new applications to genomics, W Hori. IBC Library Series, Southborough, MA 1997; 4.2.1–4.2.10
   Google Scholar
• Saffran DC, Reiter RE, Jakobovits A, Owen NW. Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev 1999; 18: 437–449
   PubMed Web of Science ®Google Scholar
• Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81–85
   PubMed Web of Science ®Google Scholar
• Sinha AA, Sackrison JL, DeLeon OF, Wilson MJ, Gleason DF. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis. Anat Rec 1996; 245: 652–661
   PubMedGoogle Scholar
• Sinha AA, Quast BJ, Reddy PK, Erlson MK, Wilson MJ. Intravenous injection of an immunoconjugate (anti-PSA–IgG conjugated to 5-fluoro-2′-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anticancer Res 1999; 19: 893–902
   PubMed Web of Science ®Google Scholar
• Todorova K, Zouback S, Mincheff M, Kyurkchiev S. Biochemichal nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines. Anticancer Res 2005; 25(6C)4727–4732
   PubMed Web of Science ®Google Scholar
• Troyer JK, Beckett ML, Wright GL, Jr. Location of prostate specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997; 30(4)232–242
   PubMed Web of Science ®Google Scholar
• Wright GL, Jr., Haley C, Beckett ML, Schellhammer PF. Expression of prostate specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol 1995; 1: 18–28
   PubMedGoogle Scholar
• Wright GL, Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326–334
   PubMed Web of Science ®Google Scholar